Ipamorelin in India | Prime Peptide

Name: Ipamorelin
Brand: Prime Peptide
SKU: PR-IP10
Price: 2999.0 INR
Availability: InStock

PRODUCT OVERVIEW

What is Ipamorelin?

Ipamorelin is a selective growth-hormone secretagogue studied in laboratory models involving ghrelin-receptor signaling, pituitary growth-hormone release, endocrine pathway selectivity, and receptor-response timing.

Its compact pentapeptide structure is commonly used in comparative research involving GHSR agonists and growth-hormone secretagogue signaling.

Purity≥99%

Molecular Weight711.85 g/mol

SequenceAib-His-D-2-Nal-D-Phe-Lys-NH2

StorageStore refrigerated at 2–8°C

FormLyophilized powder

Research UseFor in-vitro laboratory research only

Research mechanism Product-specific pathway illustration

RESEARCH AREAS

Ipamorelin Potential Use Cases

Product-specific research applications associated with Prime Peptide Ipamorelin.

Ghrelin-receptor signaling research

Growth-hormone secretagogue studies

Pituitary response models

Receptor selectivity comparisons

Endocrine pathway assays

Peptide timing studies

KEY BENEFITS

Ipamorelin Research Highlights

Key research-oriented characteristics connected to Prime Peptide Ipamorelin.

Compact pentapeptide structure
Selective GHSR research profile
Useful for receptor-response comparisons
Suitable for timing-based study designs

SPECIFICATIONS

Ipamorelin Molecular Data

Molecular specifications for Prime Peptide Ipamorelin
Molecular Formula	C38H49N9O5
Molecular Weight	711.85 g/mol
Purity	≥99%
Appearance	White lyophilized powder
Solubility	Water-soluble
Storage	Store refrigerated at 2–8°C
Research Use	For in-vitro laboratory research only

3D Structure · Representative Model

BIOLOGICAL & MOLECULAR TARGETS

Ipamorelin Research Targets

Growth hormone secretagogue receptor 1a

GHSR-1a

G protein-coupled receptor

GHSR-1a is a G protein-coupled receptor activated by ghrelin and synthetic growth-hormone secretagogues. Ipamorelin research examines receptor-mediated signaling associated with pituitary growth-hormone release.

View reference ↗

SCIENTIFIC SOURCES

Ipamorelin Citations & References

Ipamorelin, the first selective growth hormone secretagogue

European Journal of Endocrinology 1998

Primary pharmacology study describing Ipamorelin as the pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2 and comparing its growth-hormone-releasing profile with other secretagogues in pituitary-cell and animal models. PMID: 9849822.

Read publication →

Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers

Pharmaceutical Research 1999

Human dose-escalation study modeling Ipamorelin pharmacokinetics and the time course of growth-hormone response after intravenous infusion. The paper reports dose-proportional disposition and an episodic growth-hormone response model. PMID: 10496658.

Read publication →

Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption

Xenobiotica 1998

Comparative animal pharmacokinetic study evaluating Ipamorelin and related peptidyl growth-hormone secretagogues across administration routes, including clearance, excretion, metabolic recovery and nasal absorption. PMID: 9879640.

Read publication →

TERMINOLOGY

Ipamorelin Glossary

Ipamorelin — A synthetic pentapeptide growth-hormone secretagogue studied for selective pituitary growth-hormone release.

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. Published pharmacology describes it as a growth-hormone secretagogue investigated in receptor, pituitary-cell, animal and human PK/PD studies.

Also known as: NNC 26-0161 Source ↗

Growth hormone secretagogue — A compound studied for stimulating growth-hormone release through secretagogue-receptor signaling.

A growth hormone secretagogue is a peptide or non-peptide compound investigated for stimulating pituitary growth-hormone release through growth hormone secretagogue receptor signaling. This pathway is distinct from direct activation of the GHRH receptor.

Also known as: GHS, GH secretagogue Source ↗

Growth hormone secretagogue receptor 1a — The functional ghrelin receptor subtype involved in growth-hormone secretagogue signaling.

Growth hormone secretagogue receptor 1a, abbreviated GHSR-1a, is the signaling-competent ghrelin receptor subtype. It is a G protein-coupled receptor used in binding and functional assays for ghrelin and synthetic secretagogues.

Also known as: GHSR-1a, Ghrelin receptor, Growth hormone secretagogue receptor Source ↗

COMMON RESEARCH QUESTIONS

Ipamorelin FAQ

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue identified in the scientific literature as NNC 26-0161. Its reported sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Published studies have investigated its pharmacology in isolated pituitary cells, animal models and human pharmacokinetic-pharmacodynamic experiments. This description concerns its research identity and does not establish a therapeutic use or clinical outcome.

Which receptor pathway is studied with Ipamorelin?

Ipamorelin is studied within the growth hormone secretagogue receptor pathway. Early pharmacological work described activity through a GHRP-like receptor, while later receptor research identified the functional growth hormone secretagogue receptor subtype as GHSR-1a, also known as the ghrelin receptor. This pathway is biologically distinct from direct GHRH-receptor activation, although both can be examined in relation to pituitary growth-hormone release.

What is the amino-acid sequence of Ipamorelin?

The sequence reported in the original pharmacology paper is Aib-His-D-2-Nal-D-Phe-Lys-NH2. It contains five residues and includes non-standard amino-acid components, which is why abbreviated chemical notation is used instead of a conventional one-letter protein sequence. The terminal NH2 indicates C-terminal amidation.

What evidence supports the Ipamorelin research summary?

The summary is based on peer-reviewed, PubMed-indexed research. The foundational 1998 pharmacology paper reports Ipamorelin’s sequence and selective secretagogue profile in pituitary-cell and animal models. A 1999 human study characterizes pharmacokinetics and growth-hormone response using PK/PD modeling. A separate comparative pharmacokinetic study evaluates disposition, excretion and absorption in animal models. Full citation records and official links are provided in the Sources section.

What is Ipamorelin studied for in laboratory research?

Ipamorelin has been investigated in growth hormone secretagogue receptor signaling, isolated pituitary-cell response, comparative secretagogue pharmacology, endocrine selectivity and pharmacokinetic-pharmacodynamic modeling. These research contexts describe experimental measurements such as receptor-associated signaling, growth-hormone release patterns, disposition and comparative peptide behavior. They should not be interpreted as evidence that this store product is approved for diagnosis, prevention or treatment of any condition.